Seroprevalence of SARS-CoV-2 among ICU Healthcare Workers
Archives of Medical Laboratory Sciences,
Vol. 8 (2022),
Page 1-7 (e2)
Background and Aim: Coronavirus disease-2019 (COVID-19) has affected most countries in the world. The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was first reported in late December 2019 in Wuhan, China, and then spread around the world. In Iran, the first case with a definitive test was reported on February 20 in Qom province and a month later in March, the first case was reported in Mashhad. Hospital staff is among the most susceptible groups who are more likely to be infected due to direct contact with patients. The aim of this study was to evaluate the serum prevalence of antibodies against COVID-19 in patients with or without clinical symptoms working in the Intensive Care Unit (ICU) of hospitals affiliated with Mashhad University of Medical Sciences.
Methods: The present study is a cross-sectional study of sero-epidemiological type that was conducted to investigate the serological prevalence of COVID-19 in the period from August 25 to September 30, 2020, in Mashhad. A total of 300 serum samples were collected from the ICU staff of the hospitals affiliated with Mashhad University of Medical Sciences. Sero-prevalence and 95% confidence interval (CI) were calculated for all individuals who were stratified by job title, COVID-19 risk of exposure, direct contact with patients, hospitals, and intensity of care. The significance level was set generally at p < 0.05. Data were analyzed using SPSS V.25.
Results: The total sero-prevalence of IgG N antibody was 30.67% in COVID-19 ICU healthcare workers. The most prevalence (35.21 %) was recorded in nurse assistances who have the most contact with patients. Among asymptomatic individuals, 17.1% showed to be positive without any symptoms which emphasize the risk of the virus spread from this population who are not aware of their infection. Odds ratios and 95% confidence intervals were reported in the results. The significant difference indicates a statistically significant association with a p-value less than 0.05 (P-value=0.001).
Conclusion: Our study showed that less contact with patients with COVID-19 results in a lower risk of infection. Also, there is a high percentage of positive people among the staff who did not show any symptoms of the disease.
- Taravat Bamdad; Email: email@example.com; ORCID: https://orcid.org/0000-0003-3620-0701
- Dr. Saeid Amel Jamedar; Email: Ameljs@mums.ac.ir; ORCID: https://orcid.org/0000-0003-4813-6399
Please cite this article as: Jafari M, Bamdad T, Asli S, Moghbeli F, Amel Jamedar S. Seroprevalence of SARS-CoV-2 among ICU Healthcare Workers. Arch Med Lab Sci. 2022;8:1-7 (e2). https://doi.org/10.22037/amls.v8.36039
- Mashhad, Iran
- ICU Healthcare Workers
How to Cite
Masters P, Perlman S. In Fields Virology Vol. 2 (eds Knipe, DM &Howley, PM) 825–858. Lippincott Williams & Wilkins; 2013.
Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nature Reviews Microbiology. 2019;17(3):181-92.
Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews Microbiology. 2020:1-14.
Deng S-Q, Peng H-J. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. Journal of clinical medicine. 2020;9(2):575.
Zhang J-j, Dong X, Cao Y-y, Yuan Y-d, Yang Y-b, Yan Y-q, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020;75(7):1730-41.
Ji T, Liu Z, Wang G, Guo X, Lai C, Chen H, et al. Detection of COVID-19: A review of the current literature and future perspectives. Biosensors and Bioelectronics. 2020;166:112455.
Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. Jama. 2020;323(22):2249-51.
Rostami A, Sepidarkish M, Leeflang M, Riahi SM, Shiadeh MN, Esfandyari S, et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clinical Microbiology and Infection. 2020.
Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. The Lancet. 2020;396(10247):313-9.
Verity R, Okell L, Dorigatti I. Estimates of the severity of coronavirus disease 2019: a model-based analysis (vol 20, pg 669, 2020). 2020.
Sotgiu G, Barassi A, Miozzo M, Saderi L, Piana A, Orfeo N, et al. SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital. BMC Pulmonary Medicine. 2020;20(1):1-6.
Wu H-S, Hsieh Y-C, Su I-J, Lin T-H, Chiu S-C, Hsu Y-F, et al. Early detection of antibodies against various structural proteins of the SARS-associated coronavirus in SARS patients. Journal of biomedical science. 2004;11(1):117-26.
Tan Y-J, Goh P-Y, Fielding BC, Shen S, Chou C-F, Fu J-L, et al. Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers. Clinical and diagnostic laboratory immunology. 2004;11(2):362-71.
Meyer B, Drosten C, Müller MA. Serological assays for emerging coronaviruses: challenges and pitfalls. Virus research. 2014;194:175-83.
Lipsitch M, Swerdlow DL, Finelli L. Defining the epidemiology of Covid-19—studies needed. New England journal of medicine. 2020;382(13):1194-6.
Mortezagholi S, Rostamzadeh D, Alinejad M, Younesi V, Tabarsi P, Shabani M. Prevalence of Anti-SARS-CoV-2 Specific Antibodies in Health-Care Workers Compared to General Population during an Early Phase of the Pandemic, Tehran-Iran. Iranian Journal of Immunology. 2021;18(1):82-92.
Armin S, Karbasian F, Hoseinialfatemi SM, Mansour Ghanaie R, Rafiei Tabatabaei S, Fahimzad SA, et al. Prevalence of SARS-CoV-2 Specific Antibodies in the Staff of a Children's Hospital, in Tehran, Iran. Jundishapur Journal of Microbiology. 2020;13(9).
Airoldi C, Patrucco F, Milano F, Alessi D, Sarro A, Rossi MA, et al. High Seroprevalence of SARS-CoV-2 among Healthcare Workers in a North Italy Hospital. International Journal of Environmental Research and Public Health. 2021;18(7):3343.
Rodriguez A, Arrizabalaga-Asenjo M, Fernandez-Baca V, Lainez MP, Al Nakeeb Z, Garcia JD, et al. Seroprevalence of SARS-CoV-2 antibody among healthcare workers in a university hospital in Mallorca, Spain, during the first wave of the COVID-19 pandemic. International Journal of Infectious Diseases. 2021;105:482-6.
Poustchi H, Darvishian M, Mohammadi Z, Shayanrad A, Delavari A, Bahadorimonfared A, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. The Lancet Infectious Diseases. 2021;21(4):473-81.
- Abstract Viewed: 55 times
- PDF Downloaded: 48 times